Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4766606 | 0.86 | ALDH1A1 (0.43) | ALDH1A1TSHRMEN1KMT2ALMNA | |
| SCHEMBL4019745 | 0.85 | PHF8 (0.39) | ALDH1A1TSHRMEN1KMT2ALMNA | |
| SCHEMBL499415 | 0.85 | ALDH1A1 (0.52) | ALDH1A1TSHRLMNA | |
| SCHEMBL19852484 | 0.83 | ALDH1A1 (0.55) | ALDH1A1TSHRLMNA | |
| SCHEMBL30185810 | 0.83 | ALDH1A1 (0.55) | ALDH1A1TSHRLMNA | |
| SCHEMBL23135855 | 0.82 | ALDH1A1 (0.34) | ALDH1A1TSHRMEN1KMT2ALMNA | |
| SCHEMBL5117455 | 0.82 | MEN1 (0.30) | MEN1KMT2A | |
| SCHEMBL19287916 | 0.82 | ALDH1A1 (0.40) | ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL28831979 | 0.81 | PHF8 (0.33) | ALDH1A1TSHRMEN1KMT2ALMNA | |
| SCHEMBL18270950 | 0.80 | ALDH1A1 (0.33) | ALDH1A1TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4711365-A1 | THIAZOLE DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2026-03-18 | — | — | EP | disclosed |
| EP-4699607-A2 | N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2026-02-25 | — | — | EP | disclosed |
| US-20250353836-A1 | N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMA (US) | 2025-11-20 | — | — | US | disclosed |
| EP-4347031-B1 | N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMA (US) | 2025-10-29 | — | — | EP | disclosed |
| US-12258333-B2 | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-03-25 | — | — | US | disclosed |
| WO-2024235205-A1 | THIAZOLE DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2024-11-21 | — | — | WO | disclosed |
| CN-115109075-B | Mutant IDH1 and IDH2 inhibitors | 伊莱利利公司 | 2024-09-20 | — | — | CN | disclosed |
| US-20240182455-A1 | N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) | 2024-06-06 | — | — | US | disclosed |
| EP-4347031-A1 | N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2024-04-10 | — | — | EP | disclosed |
| CN-117794920-A | N- (hydroxyalkyl (hetero) aryl) tetrahydrofurancarboxamides as sodium channel modulators | 沃泰克斯药物股份有限公司 | 2024-03-29 | — | — | CN | disclosed |
| EP-3555105-A1 | 7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AS MUTANT IDH1 AND IDH2 INHIBITORS | Eli Lilly and Company (US) | 2019-10-23 | — | — | EP | disclosed |
| US-20190134005-A1 | CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARM INC (US) | 2019-05-09 | — | — | US | disclosed |
| WO-2018111707-A1 | 7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AS MUTANT IDH1 AND IDH2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2018-06-21 | — | — | WO | disclosed |
| WO-2017214505-A1 | CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017203474-A1 | PROCESS FOR PREPARATION OF SACUBUTRIL INTERMEDIATE | DR. REDDY'S LABORATORIES LIMITED (IN) | 2017-11-30 | — | — | WO | disclosed |
| US-9744183-B2 | Nucleic acid prodrugs and methods of use thereof | WAVE LIFE SCIENCES LTD. (SG) | 2017-08-29 | — | — | US | disclosed |
| US-20160347784-A1 | NOVEL NUCLEIC ACID PRODRUGS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES PTE. LTD. (SG) | 2016-12-01 | — | — | US | disclosed |
| US-7365067-B2 | Indanol derivative | SANKYO COMPANY, LIMITED (JP) | 2008-04-29 | — | — | US | disclosed |
| US-20070197570-A1 | Indanol derivative | SANKYO COMPANY, LIMITED (JP) | 2007-08-23 | — | — | US | disclosed |
| EP-1746095-A1 | INDANOL DERIVATIVE | Sankyo Company, Limited (JP) | 2007-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12258333-B2 | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels | TRPV1, SCN2A, SCN2B | ALDH1A1 1741/4885TSHR 3394/4885MEN1 4375/4885 |
| US-20240182455-A1 | N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | TRPV1, SCN2A, SCN2B | ALDH1A1 1741/4885TSHR 3394/4885MEN1 4375/4885 |
| US-20070197570-A1 | Indanol derivative | BDKRB2, BDKRB1, TACR2 | ALDH1A1 1329/4885TSHR 407/4885MEN1 2052/4885 |
| US-20160347784-A1 | NOVEL NUCLEIC ACID PRODRUGS AND METHODS OF USE THEREOF | PNP, RNGTT, TYMP | ALDH1A1 1085/4885TSHR 3172/4885MEN1 2270/4885 |
| US-20190134005-A1 | CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE | UGCG, MAN2B1, GBA1 | ALDH1A1 2406/4885TSHR 4258/4885MEN1 1675/4885 |
| US-20250353836-A1 | N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | TRPV1, SCN2A, SCN2B | ALDH1A1 1741/4885TSHR 3394/4885MEN1 4375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.